Literature DB >> 10197646

Long-segment colon interposition for acquired esophageal disease.

J C Wain1, C D Wright, E Y Kuo, A C Moncure, E W Wilkins, H C Grillo, D J Mathisen.   

Abstract

BACKGROUND: Long-segment colon interposition has been used for esophageal replacement for acquired esophageal disease. The indications for use, morbidity, and functional results of these conduits have been debated.
METHODS: We reviewed the medical records, office visits, and operative reports of patients undergoing long colon interposition for acquired esophageal disease at our institution from 1956 to 1997.
RESULTS: Long colon interposition was performed in 52 patients for caustic injury (n = 20), gastroesophageal disease (n = 16), previous irradiation (n = 8), primary motility disorders (n = 4), and acquired absence of the esophagus (n = 4). From 1976 to 1997, acquired diseases accounted for 62% of long colon interposition. The left colon was used in 46 patients and the right colon in 6. The in-hospital mortality rate was 4%. Early complications included graft ischemia in 5 patients, anastomotic leak in 3, and small bowel obstruction in 1. Late complications included anastomotic stenosis requiring dilation in 26 patients, with 2 requiring surgical revision, and bile reflux requiring surgical diversion in 1 patient. Swallowing function was excellent in 24% of patients, good in 66%, and poor in 10%.
CONCLUSIONS: Long colon interposition can be performed safely, with acceptable long-term functional results in patients with acquired esophageal disease.

Entities:  

Mesh:

Year:  1999        PMID: 10197646     DOI: 10.1016/s0003-4975(99)00029-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  16 in total

1.  Functional outcome following colon interposition in total pharyngoesophagectomy with or without laryngectomy.

Authors:  Mieke Moerman; Hossein Fahimi; Wim Ceelen; Piet Pattyn; Hubert Vermeersch
Journal:  Dysphagia       Date:  2003       Impact factor: 3.438

2.  Ileo-right colonic reconstruction preserving all four colonic vessels after esophagectomy for cancer.

Authors:  Shirou Kuwabara; Kazuaki Kobayashi; Hiroaki Uehara; Makoto Aoki; Akira Kubota; Masaru Komatsu; Rina Harada; Shiori Utsumi
Journal:  Updates Surg       Date:  2021-03-20

3.  Anatomical Description and Clinical Relevance of a Rare Variation in the Mesenteric Arterial Arcade Pattern.

Authors:  Ranjeeta Hansdak; Rohini Pakhiddey; Avinash Thakur; Vandana Mehta; Gayatri Rath
Journal:  J Clin Diagn Res       Date:  2015-08-01

Review 4.  Cervical exenteration.

Authors:  Uma M Sachdeva; Michael Lanuti
Journal:  Ann Cardiothorac Surg       Date:  2018-03

Review 5.  Esophageal reconstruction with colon tissue.

Authors:  Takushi Yasuda; Hitoshi Shiozaki
Journal:  Surg Today       Date:  2011-05-28       Impact factor: 2.549

Review 6.  Jejunal graft conduits after esophagectomy.

Authors:  Puja Gaur; Shanda H Blackmon
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 7.  European perspective in Thoracic surgery-eso-coloplasty: when and how?

Authors:  Lucile Gust; Moussa Ouattara; Willy Coosemans; Philippe Nafteux; Pascal Alexandre Thomas; Xavier Benoit D'Journo
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

8.  Colonic Interposition After Adult Oesophagectomy: Systematic Review and Meta-analysis of Conduit Choice and Outcome.

Authors:  Jade Brown; Wyn G Lewis; Antonio Foliaki; Geoffrey W B Clark; Guy R J C Blackshaw; David S Y Chan
Journal:  J Gastrointest Surg       Date:  2018-03-08       Impact factor: 3.452

Review 9.  Peculiarities of intra-thoracic colon interposition-eso-coloplasty: indications, surgical management and outcomes.

Authors:  Lucile Gust; Henri De Lesquen; Ilies Bouabdallah; Geoffrey Brioude; Pascal-Alexandre Thomas; Xavier-Benoit D'journo
Journal:  Ann Transl Med       Date:  2018-02

10.  Transhiatal esophageal resection for corrosive injury.

Authors:  Narendar Mohan Gupta; Rajesh Gupta
Journal:  Ann Surg       Date:  2004-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.